Skip to main content

Infection and Immunity in pediatric patients

The Infection and Immunity in pediatric patients research group is a multidisciplinary pediatric research group made up of health professionals involved in translational research in the field of pediatric infectious diseases and immunodeficiencies, two related fields in terms of pathophysiology and clinical implications. It is a consolidated research group recognized by the AGAUR and is the only one with the accreditation of the Jeffrey Modell Foundation in research in the field of primary immunodeficiencies throughout the state.

The group was officially created in 2010, belongs to the area of Infectious Diseases and participates in the transversal programs of Advanced Translational Immunology and Rare Diseases and actively participates in national and international competitive projects, carries out multiple academic and industry-linked clinical trials and has increased the number and quality in recent years. In addition, it has its own laboratory specially dedicated to advanced immune studies.

Research lines

Optimization of diagnosis and treatment of tuberculosis, imported diseases ans sexually transmitted diseases [Infectious diseases]

IP: Antoni Soriano Arandes, Maria Espiau Guarner

Optimization of therapeutic approaches in pediatric patients with IEI [Innate errors of immunity (IEI)]

IP: Jacques Gabriel Rivière, Pere Soler Palacín

The use of biomarkers in pediatric patients with IEI [Innate errors of immunity (IEI)]

IP: Jacques Gabriel Rivière, Pere Soler Palacín

Viral infections in children [Infectious diseases]

IP: Jorgina Vila Soler, Pere Soler Palacín

Blog

News

The meeting, held in Barcelona, provided an opportunity to present the project's main findings and establish new avenues of collaboration among the consortium members.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The project, in which Vall d’Hebron participates, studied the Bimervax® vaccine in immunocompromised individuals and paediatric patients.